Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Esophageal Varices-II: Clinical Features and Management01:28

Esophageal Varices-II: Clinical Features and Management

122
Esophageal varices often manifest as gastrointestinal bleeding episodes, presenting symptoms like hematemesis (vomiting of blood), hematochezia (passing fresh blood via the rectum), and melena (black, tarry stools). Other signs can include weight loss, anorexia, abdominal discomfort, jaundice, pruritus, altered mental status, and muscle cramps.
In the initial assessment, a thorough review of the patient's medical history is vital to identify risk factors such as liver disease, alcohol...
122
Hepatic Drug Excretion: Enterohepatic Cycling01:17

Hepatic Drug Excretion: Enterohepatic Cycling

1.7K
Enterohepatic cycling involves the active secretion of drugs and their metabolites into the bile via transporters in the canalicular membrane of hepatocytes. This secretion is an integral part of the digestive process, releasing these substances into the gastrointestinal (GI) tract.
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
1.7K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

640
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
640
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

249
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
249
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists01:30

Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists

196
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
196
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

197
The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
197

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Breast Cancer and Metabolic Dysfunction-Associated Steatotic Liver Disease.

International journal of molecular sciences·2026
Same author

Prevalence and Association of Liver Steatosis and Non-Alcoholic Pancreatic Steatosis in Very High Cardiovascular Risk.

Diseases (Basel, Switzerland)·2026
Same author

Current management of MASLD in type 2 diabetes.

Hormones (Athens, Greece)·2026
Same author

Metabolic Dysfunction-Associated Steatotic Liver Disease after Pancreatoduodenectomy: an Underestimated Metabolic Complication Driven by Unique Pathophysiological Mechanisms.

Journal of gastrointestinal cancer·2026
Same author

Bariatric Surgery in the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease: Long-Term Benefits for Liver Health.

Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists·2026
Same author

Mini-Review: The Detoxification Effects of Black Radish in Metabolically Dysfunctional-Associated Fatty Liver Disease.

International journal for vitamin and nutrition research. Internationale Zeitschrift fur Vitamin- und Ernahrungsforschung. Journal international de vitaminologie et de nutrition·2026

Related Experiment Video

Updated: Aug 28, 2025

Real-Time Dynamic Collection of Hippocampal Extracellular Fluid from Conscious Rats Using a Microdialysis System
05:43

Real-Time Dynamic Collection of Hippocampal Extracellular Fluid from Conscious Rats Using a Microdialysis System

Published on: October 21, 2022

2.5K

Current approaches to hepatic encephalopathy.

Paulina Vidal-Cevallos1, Norberto C Chávez-Tapia1, Misael Uribe1

  • 1Obesity and Digestive Disease Unit, Medica Sur Clinic and Foundation, Puente de Piedra 150, col. Toriello Guerra, C.P. 14050, Mexico City, Mexico.

Annals of Hepatology
|September 17, 2022
PubMed
Summary
This summary is machine-generated.

Hepatic encephalopathy (HE) is a liver condition affecting brain function. Current treatments focus on overt HE, but more research is needed for minimal HE diagnosis and management.

Keywords:
ClassificationDiagnosisLiver cirrhosisPhysiopathologyTherapeutics

More Related Videos

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube
06:12

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube

Published on: April 28, 2020

11.4K
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.2K

Related Experiment Videos

Last Updated: Aug 28, 2025

Real-Time Dynamic Collection of Hippocampal Extracellular Fluid from Conscious Rats Using a Microdialysis System
05:43

Real-Time Dynamic Collection of Hippocampal Extracellular Fluid from Conscious Rats Using a Microdialysis System

Published on: October 21, 2022

2.5K
Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube
06:12

Inducing Acute Liver Injury in Rats via Carbon Tetrachloride CCl4 Exposure Through an Orogastric Tube

Published on: April 28, 2020

11.4K
Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen
09:44

Generation of a Rat Model of Acute Liver Failure by Combining 70% Partial Hepatectomy and Acetaminophen

Published on: November 27, 2019

10.2K

Area of Science:

  • Hepatology
  • Neurology
  • Gastroenterology

Background:

  • Hepatic encephalopathy (HE) is a brain dysfunction linked to liver insufficiency or portosystemic shunts.
  • 30-40% of cirrhosis patients experience overt HE; its pathophysiology involves hyperammonaemia, inflammation, and oxidative stress.
  • Minimal HE presents cognitive abnormalities detectable only by specific tests, while overt HE is diagnosed clinically.

Purpose of the Study:

  • To review the current understanding of hepatic encephalopathy pathophysiology and management.
  • To highlight the diagnostic challenges and treatment controversies, particularly for minimal HE.
  • To emphasize the need for improved diagnostic tools and treatment strategies for HE.

Main Methods:

  • Literature review of HE pathophysiology, diagnosis, and treatment.
  • Analysis of current clinical guidelines and research gaps.
  • Discussion of emerging factors like glutaminase gene alterations.

Main Results:

  • Overt HE is the current focus for routine treatment, aiming to improve mental status and address precipitating factors.
  • Treatment strategies target ammonia reduction and elimination.
  • Indications for treating minimal HE remain controversial despite its impact on quality of life.

Conclusions:

  • Significant unanswered questions remain regarding HE pathophysiology and optimal management.
  • Development of more accurate and objective diagnostic methods for overt HE is crucial for early detection.
  • Improved diagnostics and treatments are needed to enhance patient quality of life and reduce economic burden.